

Nina Le Bert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7421128/publications.pdf>

Version: 2024-02-01

32
papers

5,154
citations

257450

24
h-index

414414

32
g-index

41
all docs

41
docs citations

41
times ranked

9716
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. <i>Nature</i> , 2022, 601, 110-117.	27.8	280
2	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. <i>Med</i> , 2022, 3, 104-118.e4.	4.4	38
3	Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients. <i>Blood</i> , 2022, 140, 156-160.	1.4	10
4	Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	20
5	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. <i>Nature Biotechnology</i> , 2022, 40, 1680-1689.	17.5	29
6	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. <i>Cell Reports</i> , 2021, 34, 108728.	6.4	568
7	Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	259
8	Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. <i>Med</i> , 2021, 2, 682-688.e4.	4.4	152
9	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. <i>Lancet Microbe</i> , The, 2021, 2, e240-e249.	7.3	322
10	Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. <i>Cell Reports</i> , 2021, 36, 109570.	6.4	86
11	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	89
12	SARS-CoV-2-specific T cells in infection and vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2307-2312.	10.5	131
13	Therapeutic vaccine BR11-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. <i>JHEP Reports</i> , 2021, 3, 100361.	4.9	24
14	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. <i>Oxford Open Immunology</i> , 2021, 2, .	2.8	59
15	Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men. <i>Emerging Microbes and Infections</i> , 2021, 10, 2141-2150.	6.5	20
16	Difference in sensitivity between SARS-CoV-2-specific T cell assays in patients with underlying conditions. Reply. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	4
17	Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 34-44.	3.7	57
18	Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy. <i>JHEP Reports</i> , 2020, 2, 100062.	4.9	42

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. <i>Nature</i> , 2020, 584, 457-462.	27.8	1,744
20	Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. <i>Gastroenterology</i> , 2020, 159, 652-664.	1.3	102
21	Fine-tuning TLR7-Based Therapy for Functional HBV Cure. <i>Hepatology Communications</i> , 2019, 3, 1289-1292.	4.3	10
22	Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. <i>Nature</i> , 2019, 574, 200-205.	27.8	135
23	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. <i>Gastroenterology</i> , 2019, 156, 1862-1876.e9.	1.3	92
24	PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. <i>Journal of Clinical Investigation</i> , 2018, 128, 4573-4587.	8.2	188
25	Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. <i>Journal of Clinical Investigation</i> , 2018, 128, 668-681.	8.2	167
26	Immunotherapy for Chronic Hepatitis B Virus Infection. <i>Gut and Liver</i> , 2018, 12, 497-507.	2.9	76
27	Genome-Derived Cytosolic DNA Mediates Type I Interferon-Dependent Rejection of B Cell Lymphoma Cells. <i>Cell Reports</i> , 2015, 11, 460-473.	6.4	149
28	STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression. <i>Oncotarget</i> , 2014, 3, e29259.	4.6	18
29	Advances in NKG2D ligand recognition and responses by NK cells. <i>Immunology and Cell Biology</i> , 2014, 92, 230-236.	2.3	48
30	RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma. <i>Cancer Research</i> , 2014, 74, 2193-2203.	0.9	127
31	Regulation of self-ligands for activating natural killer cell receptors. <i>Annals of Medicine</i> , 2013, 45, 384-394.	3.8	26
32	DC Priming by <i>M. vaccae</i> Inhibits Th2 Responses in Contrast to Specific TLR2 Priming and Is Associated with Selective Activation of the CREB Pathway. <i>PLoS ONE</i> , 2011, 6, e18346.	2.5	29